This CME/CNE program is derived from content presented at the Congress of Clinical Rheumatology 2019. The expert faculty will provide clinicians with an update on the hot topic of systemic sclerosis interstitial lung disease (SSc-ILD) as it relates to patient care in rheumatology. The expert faculty will review pathophysiology and recent treatment guidelines for accurate detection and diagnosis of SSc-ILD. New clinical trial data of SSc-ILD therapeutics will be analyzed, debating the clinical relevance in the rheumatology treatment landscape. Best practices for optimally managing patients with SSc-ILD and other comorbidities, particularly adverse events, will be highlighted. This CME/CNE activity will provide clinicians with practical information for improving care of systemic sclerosis interstitial lung disease patients.
Rheumatologists, pulmonologists, primary care physicians, internists, nurses, nurse practitioners, physician assistants, and other health care providers that are involved in the management of SSc-ILD
- Understand basic pathological progression underlying disability and death in SSc-ILD
- Recognize risk factors that predict death and disability in SSc-ILD
- Become familiar with assessment tools for screening and monitoring of SSc-ILD
- Understand the repertoire of potential treatments in SSc-ILD
- Consider important non-pharmaceutical management in SSc-ILD
Lesley Ann Saketkoo, MD, MPH
Associate Professor Clinical Immunology
Associate Professor of Medicine
New Orleans, Louisiana
Mary Beth Scholand, MD
Director, Interstitial Lung Disease Clinic
Assistant Professor in Pulmonary Medicine
The University of Utah
Salt Lake City, Utah
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
|Faculty||Relationship Identified With:|
|Lesley Ann Saketkoo, MD, MPH||Consultant/Advisor: Amgen Inc.; Boehringer Ingelheim; Corbus Pharmaceuticals; Genentech, Inc.; Gilead Pharmaceuticals; Kroger; Mallinckrodt Pharmaceuticals; Untied Therapeutics|
|Mary Beth Scholand, MD||Consultant/Advisor: Boehringer Ingelheim; Genentech, Inc.Speaker’s Bureau: Boehringer Ingelheim; Genentech, Inc.|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hours). Provider number P0491.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Boehringer Ingelheim.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Boehringer Ingelheim do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
8. 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].